ASH Annual Meeting

Matthew Matasar, MD, discusses real-world data on treatment options for diffuse large B-cell lymphoma.

GC012F/AZD0120 CAR T-cell therapy shows 100% response rate in newly diagnosed multiple myeloma, offering hope for diverse patient groups.

Remote monitoring enhances infection management in hematologic malignancies, reducing hospitalizations and improving patient communication for better outcomes.

Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated DLBCL patients, without rituximab.

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

Dr. Robert Orlowski highlights strategies to prevent infections in multiple myeloma patients treated with linvoseltamab, emphasizing antiviral prophylaxis and IVIG use.

Explore the significance of MRD negativity in cancer prognosis and its implications for treatment strategies in community-based practices.

A recent study highlights asciminib's effectiveness in treating newly diagnosed CML, showing promising molecular response rates and safety profiles.

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

New data reveals that the BPd treatment combination significantly improves outcomes in relapsed multiple myeloma, outperforming traditional therapies.

A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.

The MonumenTAL-2 study reveals promising results for talquetamab and pomalidomide in treating relapsed/refractory multiple myeloma, showcasing high response rates.

Researchers explore the safety and efficacy of consolidating cevostamab with BCMA CAR T therapy for relapsed multiple myeloma, highlighting management protocols.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

KLN-1010 shows promising MRD-negative responses in relapsed/refractory multiple myeloma patients, highlighting its potential as a safe, off-the-shelf CAR T therapy.

The LimiTEC trial reveals that discontinuing teclistamab after 6-9 months yields comparable outcomes to continuous treatment in multiple myeloma patients.

A 6-month complete response predicts improved long-term survival in high-risk large B-cell lymphoma patients treated with axicabtagene ciloleucel.

Dexamethasone prophylaxis significantly reduces severe neurotoxicity in LBCL patients receiving axi-cel, enhancing safety without compromising efficacy.

Discover how a remote therapeutic monitoring system enhances patient care and streamlines clinic operations, reducing hospitalizations for hematologic malignancies.

A phase 1b/2 trial reveals MK-1045 shows manageable safety and promising efficacy in treating relapsed/refractory B-cell acute lymphoblastic leukemia.

Remote therapeutic monitoring significantly lowers infection-related hospitalizations in hematological cancer patients, enhancing outpatient care and reducing emergency visits.

The MANIFEST-2 trial reveals that pelabresib combined with ruxolitinib significantly improves outcomes for myelofibrosis patients compared to standard treatments.

New data from the SEQUOIA trial highlights the effectiveness of zanubrutinib and venetoclax in achieving high progression-free survival rates in CLL/SLL patients.

Families of children with acute lymphoblastic leukemia face significant financial challenges during treatment, with many experiencing material hardship and income loss.

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.

The MajesTEC-3 trial showed that teclistamab combined with subcutaneous daratumumab improved overall survival vs standard daratumumab-based regimens in relapsed/refractory multiple myeloma.

Pirtobrutinib shows significant improvement in progression-free survival for untreated CLL/SLL, potentially setting a new standard of care.

Sonrotoclax shows promising efficacy and tolerability in treating relapsed mantle cell lymphoma, with ongoing trials to confirm its potential.